Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting EPHA2 signaling for sepsis

August 1, 2024 4:17 PM UTC

Inhibiting the interaction between the receptor tyrosine kinase EPHA2 and its ligand EFNA1 could help treat sepsis by decreasing lung endothelial cell dysfunction.

EPHA2 and EFNA1 protein expression were higher in serum from pediatric septic patients than individuals without sepsis, and higher EPHA2 and EFNA1 expression levels were associated with higher levels of organ dysfunction and serum endothelial activation and dysfunction biomarkers. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article